TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in ...

BILLINGS - Staff from St. Vincent Healthcare met at their Regional Neuroscience Center for the grand opening of their brand new state-of-the-art Multiple Sclerosis Infusion Center. Doctors, patients ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

Multiple Sclerosis is a chronic disease in which the body attacks itself by mistake. Some people may never have symptoms, for others, MS can be debilitating; it's incurable, but medications can help ...

Poster Presentation Title: No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections with Long-Term Ublituximab Treatment in Patients with Relapsing Multiple Sclerosis ...

Multiple sclerosis (MS) is a disease that looks different in everyone who has it—and you may know more people who have it than you think. According to Thomas Shoemaker, MD, a RUSH neurologist and MS ...

The rapid proliferation of high-efficacy disease-modifying therapies for multiple sclerosis (MS) has revolutionized the treatment landscape, yet significant gaps remain in how health systems organize ...

Disease-modifying therapies slow down the progression of multiple sclerosis. Beta interferon drugs reduce MS attacks by altering the immune response. Copaxone and Glatopa mimic a protein in myelin to ...

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ...